Articles · HRT

Testosterone Therapy for Women: What the Evidence Shows

What trials show about low desire, off-label prescribing, and the long-term unknowns.

6 min read · Published May 30, 2026 · Updated September 29, 2026

Sourced from peer-reviewed research and clinical guidelines, cited at the end of this article. How we write about your body.

Testosterone Therapy for Women: What the Evidence Shows

Testosterone is made in the ovaries and adrenal glands throughout a woman’s reproductive life. Levels start to fall gradually from the mid-30s, separate from menopause, and by the postmenopausal years circulating testosterone is typically 50% lower than in young adulthood.

Even so, testosterone therapy for women gets far less clinical attention than estrogen. Part of the reason is that no regulator has approved a female-specific testosterone product in most countries. Women who get it are using male products off-label at much lower doses. This gap has led to a lot of inconsistency in prescribing and monitoring.

The evidence base is now solid enough that several major international societies have issued formal guidance supporting testosterone for one specific reason: low sexual desire that causes distress (hypoactive sexual desire disorder, or HSDD) in postmenopausal women.

The Evidence Base

In 2021 the International Society for the Study of Women’s Sexual Health (ISSWSH) published the first formal clinical practice guideline for testosterone use in women.[1] It drew on a review of 36 randomised trials covering more than 8,000 women, and its conclusions were endorsed by the British Menopause Society, the International Menopause Society, and the Endocrine Society.

The recommendation: transdermal testosterone at physiological female doses (aiming for a blood testosterone in the premenopausal female range, roughly 150 to 300 micrograms a day) for postmenopausal women with HSDD.[1]

HSDD means persistent or recurrent low sexual desire together with personal distress. The distress part matters: many women have lower desire in midlife without finding it distressing, and treatment is for those who do.

The Davis and colleagues trial (the largest single trial in this area, with 814 postmenopausal women) found that transdermal testosterone at 300 mcg/day produced clear improvements in sexual function and reductions in distress compared with placebo, in women not also taking estrogen.[2]

What Testosterone Improves

The evidence is strongest for four outcomes:[1][2]

Sexual desire rises in most women who reach physiological testosterone levels. This is the main evidence base and the reason HSDD is the established reason to prescribe.

Arousal and response improve alongside desire. Many women report not just wanting sex more often but easier arousal and more reliable orgasm.

Satisfaction with sex and reduced distress about the low desire are the outcomes measured in trials, and both improve consistently.

Genital sensitivity may improve, though this is less studied and is partly handled by local estrogen for GSM separately.

Claims That Run Ahead of the Evidence

Energy and fatigue. The idea that testosterone restores energy in postmenopausal women is widespread and plausible given its role in male physiology, but trial evidence is not strong enough to support prescribing for fatigue as a main reason. Some women report more energy as a side effect, but controlled data are limited.

Thinking and memory. There are mechanistic reasons to expect testosterone might support cognition, and some observational data look promising, but high-quality trial evidence for cognitive outcomes in postmenopausal women is not enough to make confident claims.

Mood. There is a general link between testosterone levels and mood in some studies, and women on testosterone occasionally report mood improvements. The data do not support testosterone as a treatment for mood disorders in women.

These reflect the honest state of the evidence, not a dismissal of reported benefits.

Prescribing and Monitoring

Because no female-specific product is approved in most countries, prescribers use male testosterone gel or cream at doses adjusted down to produce female-physiological blood levels.

Target blood level: total testosterone in the upper premenopausal female range, well below the male range. Prescribing above this target raises the risk of androgenic side effects without adding benefit.

Monitoring should include testosterone levels at baseline and at three to six months after starting, to confirm the dose is producing appropriate rather than above-normal levels.

The transdermal route (gel or cream on the inner thigh or abdomen) is preferred over injections, which produce unstable and often above-normal peaks.

Side Effects at Appropriate Doses

Deepening of the voice, more body hair pattern changes, and clitoral enlargement are linked to above-normal doses (male-range blood levels). At female-physiological doses, the reported rate of androgenic side effects is below 5%.[1]

The most common side effects at appropriate doses are:

Both depend on the dose. Keeping testosterone in the premenopausal female range greatly reduces the chance of either.

Long-Term Unknowns

Long-term data on heart outcomes, breast cancer risk, and bone health for women using testosterone are limited. The trials done so far have not been large enough or long enough to detect small differences in rare outcomes.

The ISSWSH guideline notes there is no evidence of harm at physiological doses based on the available data, while acknowledging this is not the same as established long-term safety.[1] Women considering testosterone should understand that it is supported by a meaningful trial evidence base for sexual function, that no specific safety signals have appeared, and that long-term safety data beyond five years are sparse.

Who Should Consider It

Testosterone therapy is most clearly indicated for postmenopausal women with significantly reduced sexual desire that causes personal distress, who have already had other relevant factors looked at: relationship dynamics, genital and urinary symptoms, medications affecting libido, mood, and sleep.

HSDD is underdiagnosed because many women do not raise it with clinicians. Reduced sexual desire that causes real distress is a recognised condition with an evidence-based treatment. Raising it directly with a prescriber is appropriate.


References

[1] Parish, S. J., Simon, J. A., Davis, S. R., et al. (2021). International Society for the Study of Women’s Sexual Health Clinical Practice Guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. Journal of Sexual Medicine, 18(5), 849-867. https://pubmed.ncbi.nlm.nih.gov/33797277/

[2] Davis, S. R., Moreau, M., Kroll, R., et al. (2008). Testosterone for low libido in postmenopausal women not taking estrogen. New England Journal of Medicine, 359(19), 2005-2017. Cited in: Clinical management of testosterone replacement therapy review. https://pmc.ncbi.nlm.nih.gov/articles/PMC9674516/

Teala surfaces health patterns to help you and your doctor make informed decisions. It does not diagnose conditions or replace medical advice. Always consult a qualified healthcare professional about your symptoms and treatment.